Rapid, potent and durable viral
suppression, with fewer
medicines vs. 3DRs[1–3]

DOVATO is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.[3]

Confidence from the start[1,2,4,5]

DOVATO is supported by a wealth of clinical trials and real-world studies, including >4,000 people naïve to treatment living with HIV.[1,2,4–6]

Demonstrated viral suppression in clinical data of newly diagnosed people with:

  • CD4+ T-cell count ≤200 cells/mm3[1]
  • Baseline viral load >500,000 copies/mL[1]

Efficacy reinforced in these populations vs. BIC/FTC/TAF in a real-world setting, with fewer medicines[3,7]

Review efficacy data

Long-term data up to ~3 years[2]

Explore long-term data

Robust viral suppression in people rapidly starting ART[4,5]

See rapid ART initiation

Effectiveness reinforced in a growing body of real-world data[7–19]

  • Summary of real-world evidence

    High response rates across distinct cohorts

    Adapted from a systematic literature review of DTG+3TC from real-life cohorts including: Wei Y et al. 2023; Philibert P et al. 2024; Calza L et al. 2025; Suárez-García I et al. 2025; Gan L et al. 2024; Hidalgo-Tenorio C et al. 2022; Yang J et al. 2025; Cheng C et al. 2024; Allavena C et al. 2024; Benson P et al. 2024; Cabello-Ubeda A et al. 2025; Hou H et al. 2024;
Schuettfort G et al.2024[7–19]

    Graph includes discrete cohorts reporting applicable effectiveness outcomes for N ≥50 people naïve to treatment receiving DTG+3TC; reported effectiveness outcomes vary between studies; potential overlap between cohorts cannot be ruled out. CARAVEL, DRAGON, Dat’AIDS and TANDEM included a mix of naïve to treatment and treatment
experienced people living with HIV.[7–19]

The confidence of a proven high barrier to resistance[1–3]

Discover barrier to resistance

A well-established safety profile[3]

Explore safety data

*n=5 people excluded due to missing data or not completing follow-up.[18]
†55 people were included in the PP analysis.[10]
‡4 participants lost to follow-up. In total, 141 participants were included in the PP analysis.[11]
§77 people were included in the PP analysis.[13]
||Although DRAGON data at Week 96 is available, the effectiveness outcome of HIV-1 RNA <50 copies/mL has not been reported for Week 96 data.[16,20]
Although 252 people we included in the study, only 251 had available data at database lock.[15]
#Median time over which people naïve to treatment became suppressed was 10.4 weeks. Median time on treatment was 1.3 years.[8]
††162 people were included in the PP analysis.[9]

3DR, 3-drug regimen; 3TC, lamivudine; ART, antiretroviral therapy; BIC, bictegravir; DTG, dolutegravir; FDA, United States Food and Drug Administration; FTC, emtricitabine; ITT, intention-to-treat; ITT-E, intention-to-treat-exposed; M=F, missing=failure; PP, per-protocol; TAF, tenofovir alafenamide.

References:

  1. Figueroa M et al. Clin Infect Dis 2025. https://doi.org/10.1093/cid/ciaf415. [Epub ahead of print].
  2. Cahn P et al. AIDS 2022; 36(1): 39–48.
  3. DOVATO (dolutegravir/lamivudine) Summary of Product Characteristics (SmPC).
  4. Cordova E et al. Lancet HIV 2025; 12(2): e95–e104.
  5. Rolle C et al. Open Forum Infect Dis 2023; 10(3): ofad101.
  6. ViiV Healthcare. Data on File. REF-294793. 2025
  7. Schuettfort G et al. Poster presented at HIV Glasgow. 10–13 November 2024. Glasgow, UK. P057.
  8. Benson P et al. Infect Dis Ther 2024; 13(4): 875–889.
  9. Cabello-Ubeda A et al. J Acquir Immune Defic Syndr 2025. 100(2): e4–e7.
  10. Calza L et al. J Acquir Immune Defic Syndr 2025; 99(1): 93–97.
  11. Gan L et al. Expert Rev Anti Infect Ther 2024; 22(10): 877–884.
  12. Suárez-García I et al. J Antimicrob Chemother 2025; 80(3): 682–691.
  13. Hidalgo-Tenorio C et al. Viruses 2022; 14(3): 524.
  14. Hou H et al. Medicine 2024; 103(27): e38558.
  15. Allavena C et al. Poster presented at HIV Glasgow. 10–13 November 2024. Glasgow, UK. P059.
  16. Cheng C et al. Poster presented at AIDS 2024. 22–26 July. Munich, Germany. TUPEB111. 
  17. Yang J et al. J Med Microbiol 2025; 74(1): 001949.
  18. Philibert P et al. Poster presented at HIV Drug Therapy Glasgow. 10–13 November 2024. Glasgow, UK. P082.
  19. Wei Y et al. Chin Med J 2023; 136(22): 2677–2685.
  20. Yang C et al. Poster presented at the International AIDS Society (IAS) Conference on HIV Science. 13–17 July 2025. Kigali, Rwanda. EP0146.

PM-GB-DLL-WCNT-250005 | February 2026

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.